Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 3Biliary Tract Neoplasms 3Adenocarcinoma 2Pancreatic Neoplasms 1NSCLC 1Klatskin Tumor 1HER2-positive Gastric Cancer 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Bile Duct Neoplasms 1

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2Capecitabine 2Biopsy 2toripalimab 1sacituzumab govitecan 1dehydroftorafur 1binimetinib 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Gemcitabine 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Klatskin Tumor × S 1 (combination) × Clear all
NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

AstraZeneca

Phase 3 Active not recruiting
757 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡